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T his supplement, known as the ABHACUS (Assessing the Burdenof HPV-Associated Cancers in the United States) supplement,
contains 22 articles. Together, these articles provide a comprehen-
sive snapshot of data related to the occurrence and control of multi-
ple cancers that have been associated with the human
papillomavirus (HPV). These analyses highlight the burden of HPV-
associated cancers in the US population as a whole and among vul-
nerable population subgroups. We anticipate that these findings will
be an important resource for enhancing existing strategies for the
prevention and control of HPV-associated cancers.
HPV is estimated to be responsible for 5.2% of the cancers diag-
nosed worldwide.1 Virtually 100% of cervical cancers are causally
associated with HPV, and there is increasing evidence of the role
that HPV plays in other anogenital cancers and oropharyngeal can-
cers. With the recent approval and recommendation of an HPV vac-
cine that contains HPV–16 and HPV–18, interest in quantifying the
Funded by the Centers for Disease Control and
Prevention.
This supplement to CANCER was supported by
Cooperative Agreement Number U50 DP424071-
04 from the Centers for Disease Control and Pre-
vention (CDC).
Dr. Ahmed was formerly with the Division of Can-
cer Prevention and Control at the Centers for
Disease Control and Prevention, Atlanta, Georgia.
The following registries, which cover approxi-
mately 83% of the US population, contributed
data to the production of this supplement:
Alaska, Alabama, Arkansas, California, Colorado,
Connecticut, District of Columbia, Delaware, Flor-
ida, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas,
Kentucky, Louisiana, Maine, Massachusetts,
Michigan, Minnesota, Missouri, Montana,
Nebraska, New Jersey, New Mexico, New York,
Ohio, Oklahoma, Oregon, Pennsylvania, Rhode
Island, South Carolina, Texas, Utah, Vermont,
Washington, West Virginia, and Wisconsin.
We appreciate the in–kind support from all the
contributors to this supplement. We are also
grateful for the guidance provided by the project
steering committee members: Faruque Ahmed,
Umed Ajani, Janet Bates, Apputhurai Balamura-
gan, Vicki Benard, Cheryll Cardinez, Vivien Chen,
Glenn Copeland, Michelle Cote, Steve Coughlin,
Eileen Dunne, Donatus Ekwueme, Brenda
Edwards, Anna Giuliano, Brenda Hernandez,
Claudia Hopehayn, Djenaba Joseph, Kris Khan,
Jessica King, Sue-Min Lai, Herschel Lawson,
Serban Negoita, Marsha Reichman, Tom Rich-
ards, Blythe Ryerson, Mona Saraiya, Trevor
Thompson, Jasmin Tiro, Meg Watson, Hannah
Weir, Mary White, Martin Whiteside, Phyllis
Wingo, and Xiao-Cheng Wu. Our gratitude also
goes to our team of pathologists, Diane Solomon,
Beth Unger, and Mark Sherman; to editorial and
graphic services at the Centers for Disease Con-
trol and Prevention, especially Fonda Martin, Ern-
est Martin, and Rick Hull; to Dave Stinchcomb
for creating maps; to Jessica King, Trevor
Thompson, and Kevin Zhang for the creation of
the analytic files and for data verification; to the
publication committee (Tom Richards, Mona Sar-
aiya, Phyllis Wingo, and Meg Watson); and to the
leadership of the Centers for Disease Control and
Prevention’s Division of Cancer Prevention and
Control for support of this project (Barbara Bow-
man and Robert German).
The findings and conclusions in this report are
those of the authors and do not necessarily
represent the views of the Centers for Disease
Control and Prevention.
Address for reprints: Mona Saraiya, MD, MPH, Di-
vision of Cancer Prevention and Control, Centers
for Disease Control and Prevention, 4770 Buford
Highway NE, MS K-55, Atlanta, GA 30341; Fax:
(770) 488-4639; E-mail: msaraiya@cdc.gov
Received April 14, 2008; accepted April 22,
2008.
*This article is a US Government work and, as
such, is in the public domain in the United States
of America.
ª 2008 American Cancer Society
DOI 10.1002/cncr.23753
Published online 3 November 2008 in Wiley InterScience (www.interscience.wiley.com).
2837
spectrum and burden of cancers is heightened. The
International Agency for Research on Cancer (IARC)
has determined that there is sufficient evidence for
the carcinogenicity of HPV–16 in the cervix, vulva,
vagina, penis, anus, oral cavity, and oropharynx.2
The IARC has found sufficient evidence of the role
HPV–18 plays in cervical cancer, with limited or no
evidence in other sites. Together, cervical cancer
combined with the other HPV-associated cancers
potentially afflicts an additional 25,000 persons every
year in the US.
Worldwide and in the US, the excitement and
concern surrounding the HPV vaccine has been pro-
found. The excitement derives from the potential of
the vaccine to reduce the burden of cervical cancer
in countries that have no screening infrastructure as
well as in countries such as the US, in which nearly
11,000 women each year are told they have invasive
cervical cancer and 4000 die from this disease, de-
spite the availability of screening. The HPV vaccine
also has the potential to impact a significant propor-
tion of other cancers for which there typically is no
routine screening. Conversely, the concern is that
vaccine recipients may not continue to undergo
screening for cervical cancer. Yet another concern is
that if vaccine uptake is lower in those groups at
highest risk of developing cervical cancer, current
racial/ethnic or geographic disparities could increase.
We hope that the articles in this supplement will
highlight the burden and disparities associated with
these cancers before vaccine implementation.
This supplement includes an in-depth analysis of
cancer incidence and mortality data from popula-
tion-based central cancer registries that house high-
quality data. Fourteen articles are based mainly on
cancer occurrence, using incidence data from popu-
lation-based central cancer registries that participate
in the Centers for Disease Control and Prevention
(CDC)’s National Program of Cancer Registries
(NPCR) and/or the National Cancer Institute (NCI)’s
Surveillance, Epidemiology, and End Results (SEER)
program. The NPCR program, which was established
through the Cancer Registries Amendment Act
passed by the US Congress in 1992, began providing
financial support and technical assistance to popula-
tion-based central cancer registries in 1994. This pro-
gram currently supports central registries in 45
states, the District of Columbia, and 3 US territories;
these registries cover approximately 96% of the US
population. The SEER program, which was estab-
lished as a result of the National Cancer Act of 1971,
currently supports 14 such registries and 3 supple-
mental registries, covering approximately 26% of the
US population. The population-based central cancer
registries collect information on all reportable can-
cer cases within a state or another defined geo-
graphic area. Today, the NPCR and SEER programs
together cover 100% of the US population, and data
regarding more than 1 million new invasive cancer
cases are added each year. Medical records are the
primary source of the data. Both the NPCR and
SEER data are collected and reported with the use of
uniform data items and codes, as documented by
the North American Association of Central Cancer
Registries.3 The Institute of Medicine has recognized
the importance of these 2 programs as valuable
resources for studies on cancer.4
National and regional population coverage of
cancer registry data has been achieved only within
the last few years. Such coverage now allows for the
unprecedented examination of rare cancers, as well
as a focus on cancer burden by age, sex, race, histol-
ogy, geography, and other variables. This supplement
leverages US population-based cancer registries by
demonstrating the current burden of disease for all 6
HPV-associated cancers in each of the individual
site-specific chapters (cervical, vaginal, vulvar, anal,
penile, and oropharyngeal cancers).5–10 Before enga-
ging in any analyses, the steering committee spent a
considerable amount of time establishing common
definitions. Watson et al describe the registries in
more detail and provide some standardized analytic
criteria used in the site-specific analyses.11 Benard
et al highlight some of the applications of cancer reg-
istry data, augmented with linked census-based
socioeconomic data, thereby to our knowledge
underscoring for the first time general patterns that
are observed for each of the HPV-associated can-
cers.12 Ryerson et al focus on the HPV-associated
cancer burden for oral cavity and oropharyngeal can-
cers, using anatomic subsites as a proxy for HPV
association.5
Several articles take advantage of the unique
attributes of certain central cancer registries or go
beyond the description of cancer occurrence. For
example, data from the California Cancer Registry
allow for the computation of cancer incidence rates
for Asian subpopulations, some of which have been
known to have the highest incidence of cervical can-
cer in the US.13 Despite the 1996 recommendation to
discontinue the collection of data regarding carci-
noma in situ (CIS) of the cervix, the Michigan Cancer
Surveillance System continued to collect these data;
Copeland et al present current trends related to cer-
vical CIS.14 Hopehayn et al and Coughlin et al exam-
ine the burden of cervical cancer in areas with
disproportionate burdens: Appalachia and those
states bordering Mexico.15,16 Additional articles use
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cancer registry data to examine treatment patterns
for female HPV-associated cancers and the risk of
other HPV-associated cancers among cervical cancer
survivors.17 Finally, an examination of the years of
potential life lost and mortality-related productivity
costs of all HPV-associated cancers is presented.18
Because of the importance of primary prevention
and screening for cancer control, another aim of this
supplement is to update the reader with pertinent in-
formation related to vaccination and screening.
Dunne et al describe the epidemiology of HPV and
the HPV vaccine.19 Tiro et al examine various
national behavioral surveillance systems related to
cervical cancer screening and vaccination.20 Castle
et al comment on the potential impact of the HPV
vaccine on cervical cancer screening in the years to
come.21 Whiteside et al present an overview of what
is known concerning the molecular mechanisms
involved in HPV oncogenesis to help readers inter-
pret data regarding HPV causality in noncervical can-
cers and understand the new molecular markers
proposed for screening.22 Gillison et al discuss the
role of HPV in noncervical cancers and apply world-
wide and US estimates of attributable fractions to
further define the burden of HPV-associated can-
cers.22 Another article comments on the role the can-
cer registries can play in monitoring the impact of
the HPV vaccine.23 Lastly, Khan et al describe 2 key
CDC programs related to cervical cancer prevention
(the Vaccines for Children Program) and screening
(the National Breast and Cervical Cancer Early
Detection Program) that target uninsured individuals
and other vulnerable populations.24
A few years ago, the National Coordinating
Council for Cancer Surveillance developed a national
framework for cancer surveillance in the US.25 This
supplement represents the application of this cancer
surveillance framework to HPV-associated cancers.
To be effective, cancer surveillance requires coordi-
nation and cooperation among government, profes-
sional, nonprofit, and private organizations, and the
articles contained in this supplement demonstrate
the success that can be achieved through such col-
lective efforts. Greater than 100 investigators and 30
peer reviewers from various divisions at the CDC,
various parts of the NCI, population-based cancer
registries (Arkansas, Arizona, California, Florida,
Idaho, Illinois, Kansas, Kentucky, Louisiana, Maine,
Michigan, New Mexico, New York, South Dakota,
Tennessee, Texas, and Washington DC), academic
institutions, and the American Cancer Society
worked diligently and collaboratively over the past
year and a half to produce this supplement. We wish
to express our deepest gratitude to them.
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